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Abstract: Changes at the mitochondria are an early, re- 
quired step in apoptosis in various cell types. We used 
western blot analysis to demonstrate that the proapop- 
totic protein Bax translocated from the cytosolic to the 
mitochondrial fraction in SH-SY5Y human neuroblas- 
toma cells undergoing staurosporine- or EGTA-mediated 
apoptosis. Levels of mitochondrial Bax increased 15 min 
after staurosporine treatment. In EGTA-treated cells, in- 
creased levels of mitochondrial Bax were seen at 4 h, 
consistent with a slower onset of apoptosis in EGTA 
versus staurosporine treatments. We also demonstrate 
the concomitant translocation of cytochrome c from the 
mitochondrial to the cytosolic fractions. We correlated 
these translocations with changes in caspase-3-like ac- 
tivity. An increase in caspase-3-like activity was evident 
2 h after staurosporine treatment. Inhibition of the mito- 
chondrial permeability transition had no effect on Bax 
translocation or caspase-3-like activity in staurosporine- 
treated SH-SY5Y cells. In primary cultures of cerebellar 
granule neurons undergoing low K+-mediated apoptosis, 
Bax translocation to the mitochondrial fraction was evi- 
dent at 3 h. Cytochrome c release into the cytosol was 
not significant until 8 h after treatment. These data sup- 
port a model of apoptosis in which Bax acts directly at 
the mitochondria to allow the release of cytochrome c. 
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Apoptosis is physiologically essential for the elimina- 
tion of excess neurons during nervous system matura- 
tion. The triggering of unregulated apoptosis has been 
implicated in the development of several clinically im- 
portant adult neuropathologies, including cerebral isch- 
emia (Linnick et al., 1993), Huntington's disease (Zeitlin 
et al., 1995; Goldberg et al., 1996), Alzheimer's disease 
(Nixon et al., 1994; Satou et al., 1995; Vito et al., 1996; 
Yamatsuji et al., 1996), amyotrophic lateral sclerosis 
(Troost et al., 1995), and Parkinson's disease (Ziv et al., 
I 996). 
A growing body of evidence implicates changes at the 
mitochondria, particularly the release of cytochrome c, 
as an early required step in the onset of apoptosis (Kluck 
et al., 1997; Yang et al., 1997; Green and Kroemer, 
1998). Cytochrome c released from mitochondria is a 
necessary cofactor for activation of caspase-3-like pro- 
teases (Liu et al., 1996). The cytosolic partner of cyto- 
chrome c in the apoptotic cascade has recently been 
identified as apoptosis protease-activating factor- 1 
(Apaf-1) (Li et al., 1997; Zou et al., 1997). Apaf-1 and 
cytochrome c, along with dATP, activate caspase-9. Ac- 
tivated caspase-9 mediates cleavage of pro-caspase-3 to 
active caspase-3 (Li et al., 1997; Zou et al., 1997), one of 
the principal proteases in mammalian apoptosis (Thorn- 
berry et al., 1992; Tewari et al., 1995). The mechanism 
by which cytochrome c is released from the mitochon- 
dria is unclear, but evidence is emerging supporting two 
main hypotheses: (a) release via the mitochondrial per- 
meability transition (MPT) pore or (b) release due to 
insertion and channel formation at the mitochondrial 
membrane by Bax, a proapoptotic Bcl-2 family member. 
Cytochrome c release in some cell types corresponds 
with the opening of the MPT pore (Hortelano et al., 
1997; Susin et al., 1997). Agents that prevent MPT 
attenuate apoptosis in various cell types (Marchetti et al., 
1996; Kroemer, 1997; Pastorino et al., 1998b). Trans- 
fected Bax has been shown in Jurkat T cells to act on the 
MPT pore to induce cytochrome c release (Pastorino et 
al., 1998~).  However, in the same cell line, transfected 
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Bax was reported to mediate directly the release of 
cytochrome c from the mitochondria without inducing 
MPT (Jurgensmeier et al., 1998). Several groups have 
also demonstrated that the release of cytochrome c oc- 
curs before the change in mitochondrial membrane per- 
meability (Yang et al., 1997; Bossy-Wetzel et al., 1998). 
Translocation of Bax from the cytosol to the mito- 
chondria has been previously reported (Hsu et al., 1997) 
and linked to cytochrome c release in various cell types 
(Wolter et al., 1997; Eskes et al., 1998) but has never 
been demonstrated in neuronal cells. Bax has been re- 
ported to play a pivotal role in neuronal apoptosis. Bax 
expression is elevated in apoptotic neurons (Bossen- 
meyer et al., 1998; Tamatani et al., 1998; Wullner et al., 
1998). In neurons from Bax knockout mice, Bax deletion 
reduces developmental apoptosis (White et al., 1998) and 
is essential for neurotrophic factor deprivation-induced 
apoptosis (Deckwerth et al., 1996). 
In this report, we examine whether the induction of 
apoptosis in neuroblastoma cells and neurons in primary 
culture leads to alterations in endogenous Bax localiza- 
tion. We also investigated the requirement for MPT in 
cytochrome c release and induction of caspase-3-like 
activity in SH-SY5Y human neuroblastoma cells. SH- 
SYSY cells have been used extensively in the study of 
neuronal death (Boix et al., 1997; Posmantur et al., 1997; 
Ronca et al., 1997; Fall and Bennett, 1998; Kitamura et 
al., 1998), particularly in aspects associated with Alzhei- 
mer’s disease (Peraus et al., 1997; Sheehan et al., 1997; 
Uberti et al., 1997; Parvathy et al., 1998; Shen et al., 
1998). Because the signal transduction pathway leading 
to apoptosis varies among cell types, it is important to 
investigate the relevance of processes such as Bax trans- 
location and cytochrome c release to neuronal cells un- 
dergoing apoptosis. 
MATERIALS AND METHODS 
Cell culture and treatment 
SH-SYSY human neuroblastoma cells were grown on 12- 
well plates to confluency (-2 X lo6 per well) at 37°C with 5% 
CO, in a humidified atmosphere with Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum, 
100 unitdm1 penicillin, and 100 pg/ml streptomycin. Cerebel- 
lar granule neurons were isolated as previously described (Nath 
et al., 1996b). 
At the beginning of each experiment, cultures were washed 
three times with serum-free DMEM. As indicated, cells were 
pretreated for 1 h with N-acetyl-Leu-Leu-Met-aldehyde [cal- 
pain inhibitor I1 (CalpInh 11)] or the pan-caspase inhibitor 
carbobenzoxy-Asp-CH,OC(O)-2,6-dichlorobenzene (Z-D-DCB; 
Bachem). 
Protein extraction and fractionation 
Cells were collected at the end of the treatment period by 
scraping and centrifugation at 3,600 g. Cell pellets were 
washed twice with Tris-buffered salineEDTA. Pellets were 
resuspended in S volumes of homogenization buffer: 20 m M  
HEPES (pH 7 . 3 ,  10 mM KCl, 1.5 mM MgCl,, 1 mM EGTA, 
1 mM dithiothreitol, protease inhibitor cocktail (Calbiochem), 
and 250 mM sucrose. Cells were homogenized in a Dounce 
Teflon-glass homogenizer (15 strokes). The homogenate was 
centrifuged at 500 g for 5 min to pellet out nuclei and intact 
cells. Supernatants were centrifuged at 10,000 g for 30 min. 
The 10,000-g mitochondria-rich heavy membrane pellet was 
resuspended in 100 p l  of homogenization buffer and represents 
the mitochondrial fraction. The 10,000-g supernatant is used as 
a crude cytosol. Some experiments were performed using a 
100,000-g cytosol, and results were not different from those 
with the 10,000-g supernatant. Samples were frozen at -70°C 
until use. To validate each fractionation, we performed a west- 
em blot for the mitochondrial protein Bcl-2 to ensure that it was 
restricted to the mitochondrial fraction. 
Western blotting 
Protein concentration was determined with a modified 
Lowry procedure (Bio-Rad D-C protein assay kit). Equal 
amounts of protein were loaded on each lane, electrophoresed 
on sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(4-20% acrylamide gradient gel; Novex) with a Tridglycine 
running buffer, and transferred to a polyvinylidene difluoride 
membrane (0.2 pm) by semidry electrotransfer for 2 h at 20 V. 
The blots were probed with anti-Bax (human or rat polyclonal; 
Pharmingen) or anti-cytochrome c (human monoclonal; Pharm- 
ingen) and a biotinylated secondary antibody and avidin-con- 
jugated with alkaline phosphatase (Amersham Pharmacia). The 
blots were developed with nitroblue tetrazolium and S-bromo- 
4-chloro-3-indolyl phosphate (Sigma). 
Caspase-3-like activity assay 
SH-SYSY cell lysates were prepared by Triton X-100 ex- 
traction as previously described (Nath et al., 1996b). Caspase- 
3-like activity was determined by monitoring proteolysis of the 
fluorogenic substrate acetyl-Asp-Glu-Val-Asp-7-amido-4- 
methylcoumarin (Ac-DEVD-MCA; Peptide International). 
Whole-cell lysate was added to a buffer containing 100 pM 
peptide substrate, 100 mM HEPES, 10% glycerol, 1 mM 
EDTA, and 10 mM dithiothreitol. Fluorescence (excitation at 
380 nm and emission at 460 nm) was measured every 30 min 
up to 2 h using a Millipore Cytofluor 2300 fluorescence plate 
reader. 
RESULTS 
Bax translocates from cytosolic to mitochondrial 
fraction in SH-SY5Y cells undergoing 
staurosporine-mediated apoptosis 
To investigate the localization of endogenous Bax in 
neuronal cells undergoing apoptosis, we treated SH- 
SYSY human neuroblastoma cells with staurosporine, a 
nonspecific protein kinase inhibitor and well-established 
proapoptotic agent (Koh et al., 1995; Nath et al., 1996b; 
Wiesner and Dawson, 1996). Our laboratory has demon- 
strated that caspase activity is significantly elevated 
within 2 h after staurosporine treatment in SH-SYSY 
cells (Posmantur et al., 1997). In control cells, Bax is 
primarily localized to the cytosolic fraction (Fig. 1A). 
Staurosporine treatment produced a time-dependent loss 
of Bax immunoreactivity in the cytosolic fraction and 
concomitant increase in the mitochondrial fraction (Fig. 
IA). The decrease in cytosolic Bax is apparent within 1 h 
after initiation of staurosporine treatment. The increase 
in mitochondrial Bax was significant by 30 min after the 
start of treatment (Fig. 1B; 40.9 ? 6.3% maximal den- 
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FIG. 1. Bax localization in cytosolic and mitochon- 
drial fractions in staurosporine (STS)- and EGTA- 
treated SH-SY5Y cells. A SH-SY5Y cells were un- 
treated or treated for various times with 0.5 f l  STS. 
Western blotting with Bax antibody was petformed 
on cytosolic (top; 40 pg of protein per lane) and 
mitochondrial (bottom; 20 pg of protein per lane) 
fractions. Solid arrowhead indicates intact Bax pro- 
tein (23 kDa). Open arrowhead indicates Bax frag- 
ment. B Densitometric analysis of changes in levels 
of Bax and Bax BDP in STS-treated SH-SY5Y cells. 
Intact Bax (0) and Bax BDP (0) from the mitochon- 
drial fraction are presented as mean 2 SEM (bars) 
percentages of the maximum of optical density (n 
= 3). *p < 0.05, **p < 0.01 versus control by Stu- 
dent's t test. Owing to variation between experi- 
ments, results showing loss of Bax from the cytosol 
are representative of two experiments. C: Cells were 
treated with 2 mM EGTA at the time indicated and 
assayed by western blotting for Bax in cytosolic 
(top; 40 pg of protein/lane) and mitochondrial (bot- 
tom; 20 pg of protein per lane). D: Densitometric 
analysis of Bax translocation in CGNs after 3 (solid 
columns) and 8 h (striped columns) of low K+. *p 
< 0.05, **p < 0.01 versus 0 h by Student's t test. 
Data are mean ? SEM (bars) values (n = 3). 
sitometry units for control vs. 66.6 ? 3.7% for 30 min). 
Although the level of mitochondrial Bax peaked at 2-4 
h, an 18-kDa Bax breakdown product (BDP) appeared 
beginning after 2 h of staurosporine treatment, and its 
level continued to increase throughout the treatment pe- 
riod (Fig. 1A and B). The loss of intact mitochondrial 
Bax at later time points may be attributable to this 
fragmentation. 
We investigated whether a different apoptotic stimu- 
lus, the Ca2+ chelator EGTA, would produce Bax trans- 
location. EGTA induces apoptosis in SH-SYSY cells via 
activation of caspase-3-like proteases (McGinnis et al., 
1999) and causes apoptosis in other cell types (Chiesa et 
al., 1998; Mizuno et al., 1998). Treatment with 2 mM 
EGTA led to increased mitochondrial and decreased 
cytosolic Bax immunoreactivity (Fig. 1C). Bax translo- 
cation occurred more slowly in EGTA-treated as com- 
pared with staurosporine-treated cells. Changes in Bax 
localization were not apparent until 4 h after the start of 
EGTA challenge and increased through 24 h. In EGTA- 
mediated apoptosis, no Bax fragmentation was apparent, 
consistent with the recent report that Bax fragmentation 
is due to the Ca2+-dependent protease calpain (Wood et 
al., 1998). 
To examine whether Bax translocation occurs in other 
neuronal cultures, we used primary cultures of rat cere- 
bellar granule neurons (CGNs). CGNs are a homoge- 
neous population of neurons (95%) with only a small 
amount of contaminating glial cells. These cells survive 
in vitro only when grown in 25 mM K+ and undergo 
spontaneous apoptosis in 5 mM (low) K+ (D'Mello et 
al., 1993). CGNs were untreated or exposed to low K+ 
medium for 3 or 8 h. Cytosolic Bax immunoreactivity is 
significantly reduced by 8 h. Mitochondria1 Bax immu- 
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noreactivity was elevated at 3 h (70.3 -+ 2.8% maximal 
densitometry units for control vs. 96.5 '-c 3.2% for 3 h; 
Fig. 1D) but decreased by 8 h (37 2 4.6% maximal). 
Although no Bax BDP is apparent, the loss of intact Bax 
at 8 h may be due to proteolytic degradation. A higher 
level of Bax was found in the mitochondrial fraction of 
resting CGNs compared with resting SH-SYSY cells. 
This may be attributable to a higher level of background 
death in the CGN primary culture. 
Time course of cytochrome c translocation from the 
mitochondrial to the cytosolic fraction is consistent 
with Bax translocation 
We subjected cytosolic and mitochondrial fractions 
from staurosporine- and EGTA-treated SH-SYSY 
cells to western blot analysis for cytochrome c. For 
consistency, the samples used to demonstrate cyto- 
chrome c translocation are from the same experiment 
as those used to demonstrate Bax translocation (Fig. 
1). Some cytochrome c was present in the control 
cytosol. Because there is little caspase-3-like activity 
in resting S H - S Y S Y  cells (Posmantur et al., 1997), the 
cytosolic cytochrome c may be either apo-cytochrome 
c, which lacks the heme group of holo-cytochrome c 
and does not activate caspase-3 (Kluck et al., 1997; 
Zhivotovsky et al., 1998), or cytochrome c that was 
released during sample preparation. In staurosporine- 
treated cells, an increase in cytosolic and concurrent 
loss in mitochondrial cytochrome c content were evi- 
dent after l h and reached a maximum at 4-6 h (Fig. 
2A). This time is consistent with the increase of Bax 
seen on staurosporine treatment (Fig. 1). 
In EGTA-treated SH-SYSY cells, an increase in cyto- 
solic cytochrome c did not occur until 4 h after initiating 
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FIG. 2. Cytochrome c localization in mitochondria1 and cytosolic 
fractions in staurosporine (STS)-treated SH-SY5Y cells. A. SH- 
SY5Y cells were untreated or treated for various times with 0.5 
pM STS. Western blotting with cytochrome c antibody was 
performed on cytosolic (cyto; top; 40 pg of protein per lane) and 
mitochondrial (mito; bottom; 20 pg of protein per lane) fractions. 
B: Cells were treated with 2 mM EGTA. Cytosolic (cyto; top) and 
mitochondrial (mito; bottom) fractions were assayed by western 
blotting for cytochrome c. C: Densitometric analysis of changes 
in cytochrome c localization in CGNs challenged for 8 h with low 
K+. Data are mean c SEM (bars) values (n = 3). *p < 0.05, **p 
< 0.01 versus 0 h by Student's t test. 
the challenge (Fig. 2B). This was consistent with the 
slower onset for EGTA-mediated Bax translocation. 
Loss of cytochrome c from the mitochondrial fraction 
was not obvious until 24 h of treatment. This may be 
attributed to the overall higher level of cytochrome c in 
these samples. 
We also quantified changes in levels of cytochrome 
c localization in low K+-challenged CGNs (Fig. 2C). 
No significant change occurred by 3 h (data not 
shown). By 8 h, levels of mitochondrial cytochrome c 
had significantly decreased (96.1 +- 2.1% of control 
vs. 62.0 2 6.2% of control after 8 h), and cytosolic 
cytochrome c had significantly increased (99.8 
+- 6.6% of control vs. 137.4 ? 11% of control after 
8 h). This observation is consistent with a recent report 
demonstrating elevated cytosolic cytochrome c in 
CGNs after a 5-h exposure to low K+ medium 
(Gleichman et al., 1998). Again, the high levels of 
cytochrome c in the cytosolic fraction of control 
CGNs may be attributed to a higher background death 
in these preparations compared with SH-SYSY neuro- 
blastoma cells. 
Changes in Bax and cytochrome c localization 
precede caspase activation in staurosporine-treated 
SH-SYSY cells 
We correlated the time course for the changes in Bax 
and cytochrome c localization with the activation of 
caspase-3-like proteases in staurosporine-treated SH- 
SYSY cells. We measured caspase-3-like activity in stau- 
rosporine-treated SH-SYSY cells by monitoring hydro- 
lysis of Ac-DEVD-MCA. A significant increase in 
caspase-3-like activity was detected 2 h after staurospor- 
ine treatment (Fig. 3A). Caspase-3-like activity became 
maximal at 4 h. This demonstrated that an increase in 
caspase-3-like activity follows increases in cytosolic cy- 
tochrome c, which were apparent at 1 h. 
Because both calpains and caspases are activated in 
SH-SYSY cells undergoing staurosporine-mediated apo- 
ptosis (Nath et al., 1996a,b; Posmantur et al., 1997), we 
investigated whether caspase or calpain inhibition would 
interfere with Bax translocation. Neither the pan-caspase 
inhibitor Z-D-DCB nor CalpInh I1 prevented the trans- 
location of Bax (Fig. 3B). Consistent with a recent report 
(Wood et al., 1998), we found that Bax fragmentation is 
due at least in part to calpain activity. CalpInh 11, but not 
Z-D-DCB, was able to attenuate Bax fragmentation after 
6 h of staurosporine treatment. Caspase inhibition had no 
effect on Bax BDP formation. 
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FIG. 3. Caspase activation and inhibition in staurosporine (STS)- 
treated SH-SY5Y cells. A Whole-cell lysate from 0.5 pM STS- 
treated SH-SY5Y cells was collected by Triton X-1 00 extraction 
at the indicated time. Caspase-3-like activity was assayed by 
monitoring hydrolysis of the fluorogenic substrate Ac-DEVD- 
MCA as described in Materials and Methods. Data are mean 
2 SEM (bars) values, expressed as fluorescence units per mi- 
crogram of protein (n = 4). **p < 0.01, ***p < 0.001 versus 0 h 
by ANOVA with post hoc Tukey-Kramer test. B: SH-SY5Y cells 
were pretreated with 50 pM Z-D-DCB (Z-D) or 20 pM Calplnh II 
and then treated with 0.5 pM STS. Cytosolic (40 pg) and mito- 
chondrial (mito; 20 pg) fractions were subjected to western blot 
analysis with Bax antibody. 
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FIG. 4. Bax localization and caspase activity in staurosporine 
(STS)-treated SH-SY5Y cells pretreated with MPT inhibitors. A 
SH-SY5Y cells were untreated or pretreated with 50 pM BA and 
challenged with 0.5 f l  STS for 4 h. Cytosolic (cyto; top; 40 pg) 
and mitochondrial (mito; bottom; 20 pg) fractions were probed 
for Bax and cytochrome c immunoreactivity. 8: Ac-DEVD-MCA 
hydrolysis in SH-SY5Y whole-cell lysate in cells pretreated with 
CsA or BA in the presence or absence of 50 f l  AA. Cells were 
treated for 2 h with 0.5 fl  STS. Con, control. Data are mean 
2 SEM (bars) values. 
MPT inhibition does not attenuate Bax 
translocation or caspase activation 
As Bax may exert its proapoptotic effect via induction 
of MPT (Pastorino et al., 1998b), we tested the effects of 
the MPT inhibitors bongkrekic acid (BA; 20-100 pM) 
and cyclosporin A (CsA; 100 nM-1 pM) (Marchetti et 
al., 1996; Pastorino et al., 1998~)  in our system. Neither 
inhibitor at any concentration tested provided protection 
against staurosporine-mediated apoptosis (data not 
shown). CsA alone at 500 nM was cytotoxic in SH- 
SYSY cells. Neither BA (50 phi') nor CsA (100 nM) 
prevented staurosporine-mediated Bax or cytochrome c 
translocation in SH-SYSY cells (data for BA shown in 
Fig. 4A). 
We examined whether these inhibitors affected stau- 
rosporine-mediated increases in caspase-3-like activity. 
SH-SYSY cells were pretreated with CsA or BA in the 
presence or absence of the phospholipase A, inhibitor 
aristolochic acid (AA), which enhances the protective 
effect of MPT inhibitors (Pastorino et al., 199%). Hy- 
drolysis of the fluorogenic caspase-3-like peptide sub- 
strate Ac-DEVD-MCA was measured from whole-cell 
lysate after 2 h of staurosporine treatment. We chose to 
use 2 h of treatment so that early effects of MPT inhib- 
itors on caspase activity could be detected. Staurosporine 
treatment on its own and with MPT inhibitors led to 
significantly elevated Ac-DEVD-MCA hydrolysis (Fig. 
4B). There were no differences in caspase-3-like activity 
among treatment conditions. These data suggest that 
MPT does not play a role in the onset of staurosporine- 
mediated apoptosis in SH-SYSY cells. 
DISCUSSION 
Using both human neuroblastoma cells and primary 
cultures of rat cerebellar granule neurons, we made the 
original observation that endogenous Bax translocates 
from the cytosol to the mitochondria in neuronal cells 
undergoing apoptosis. Bax translocation has been previ- 
ously found in various cell types (Hsu et al., 1997; 
Wolter et al., 1997; Coping et al., 1998) but never before 
reported in neuronal cells. Furthermore, we demon- 
strated that Bax translocation is accompanied by release 
of cytochrome c from the mitochondria in both CGNs 
and SH-SYSY neuroblastoma cells. Cytochrome c re- 
leased from the mitochondria is a required cofactor for 
caspase-3 activity, and we showed that activation of 
caspase-3 lags behind cytochrome c release. Finally, 
using two unrelated inhibitors of MPT, we concluded 
that MPT is not required for cytochrome c release and 
caspase-3-like protease activity in SH-SYSY cells. 
Our finding that Bax is predominantly cytosolic in 
resting cells and translocates to membrane fractions dur- 
ing apoptosis is consistent with recent work in nonneu- 
ronal cells (Hsu et al., 1997; Wolter et al., 1997; Coping 
et al., 1998). The fact that apoptotic signals induced Bax 
translocation in both neuroblastoma SH-SY5Y cells and 
primary cultures of CGNs suggests that Bax transloca- 
tion is a universal component of apoptosis in neuronal 
cells. Bax expression is known to be critical for neuronal 
apoptosis. For instance, cerebellar granule neurons from 
Bax -I- mice do not undergo apoptosis in response to 
5 mM K+ (Miller et al., 1997). The mechanism by which 
Bax induces apoptosis is unclear, but evidence suggests 
that Bax translocation could play a significant role. Bax 
translocation may be necessary for the formation of 
transportation pathways leading to the release of cyto- 
chrome c and/or other apoptosis-inducing factors from 
the mitochondria (Kroemer, 1997; Reed, 1997). Consis- 
tent with this, Bax has channel-forming capability in 
vitro (Schlesinger et al., 1997), and Bax insertion into the 
mitochondrial membrane is prevented by deletion of the 
carboxy tail (Wolter et a]., 1997; Coping et al., 1998), 
which protects against staurosporine-mediated toxicity 
(Wolter et al., 1997). Our results demonstrating that Bax 
translocation precedes cytochrome c release in both SH- 
SYSY cells and cerebellar granule cells suggest that this 
mechanism is functional in neurons. Because the pan- 
caspase inhibitor Z-D-DCB was unable to prevent Bax 
translocation, Bax insertion into the mitochondria is up- 
stream from caspase activation in apoptotic SH-SYSY 
cells. This is consistent with the hypothesis that Bax 
insertion leads to the release of the caspase-3 activation 
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cofactor cytochrome c as well as other putative apoptosis- 
inducing factor(s). However, this need not be identical in all 
cells because the caspase inhibitor carbobenzoxy-Val-Ma- 
Asp-fluoromethyl ketone attenuated Bax insertion in hema- 
topoietic cells (Goping et al., 1998). Ross6 et al. (1998) 
demonstrated that Bcl-2 overexpression did not prevent Bax 
translocation but did attenuate cell death, perhaps owing to 
a change in Bax:Bcl-2 stoichiometry within the mitochon- 
drial membrane. Bax may heterodimerize with Bcl-2 within 
the mitochondrial membrane, eliminating Bcl-2’s protec- 
tive effects and allowing the release of cytochrome c 
through channel formation, by breaking down the outer 
mitochondrial membrane, or by causing swelling of the mi- 
tochondrial matrix and thereby disrupting the outer mito- 
chondrial membrane. 
We demonstrated that Bax is cleaved in a Ca2+-de- 
pendent manner in SH-SYSY cells undergoing apoptosis, 
probably owing to calpain activation. Calpain-mediated 
Bax cleavage in apoptotic leukemia cells was recently 
reported (Wood et a]., 1998). A physiological function 
for Bax fragmentation has not been determined. In light 
of the recent findings that cleavage of Bcl-2 (Cheng et 
al., 1997) and Bid (Li et al., 1998; Luo et al., 1998) 
renders them proapoptotic, it is tempting to speculate that 
the Bax fragment may serve to augment proapoptotic 
effects, perhaps by facilitating its insertion or ho- 
modimerization within the mitochondrial membrane. 
However, calpain activation is not necessary for apopto- 
sis: EGTA treatment leads to apoptosis in the absence of 
calpain activation (McGinnis et al., 1999). Calpain inhi- 
bition does not prevent staurosporine-mediated apoptosis 
in SH-SYSY cells (Nath et al., 1996~).  Also, Bax cleav- 
age is not evident until late in the apoptotic process, well 
after cytochrome c release and caspase-3 activation have 
occurred. It is possible, however, that undetectable 
amounts of Bax cleavage may initiate the apoptotic pro- 
cess by augmenting Bax insertion into the mitochondrial 
membrane. 
Although essential for the release of cytochrome c and 
apoptosis in some models (Marchetti et al., 1996; 
Kroemer, 1997; Pastorino et al., 1998a), MPT is not a 
universal requirement for apoptosis. Cytochrome c re- 
lease occurs before the change in mitochondrial perme- 
ability in some systems (Yang et al., 1997; Bossy-Wetzel 
et al., 1998). Also, Bax can directly induce release of 
cytochrome c from isolated mitochondria without induc- 
ing MPT (Eskes et al., 1998; Jurgensmeier et al., 1998). 
We demonstrated that cytochrome c release and caspase- 
3-like protease activity do not seem to require MPT in 
neuronal cells. 
In summary, we have demonstrated endogenous Bax 
translocation from the cytosol to the mitochondria in 
neurons undergoing apoptosis. The translocation of Bax 
from the cytosol to the mitochondria has been reported in 
various cell types (Hsu et al., 1997; Wolter et al., 1997; 
Gross et al., 1998) but never before in neurons. We 
showed concomitant cytochrome c release from the mi- 
tochondria, which occurs before caspase-3-like activity 
and is not dependent on MPT. We propose a model in 
which Bax inserts into the mitochondrial membrane in 
response to apoptotic stimuli. Bax forms channels within 
the mitochondrial membrane through either homodimer- 
ization or heterodimerization with Bcl-2. This transport 
pathway would mediate the release of cytochrome c (and 
perhaps other caspase-activation cofactors) and result in 
caspase-3 activation leading to neuronal apoptosis. 
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